MESSAGE FROM CASTLE BIOSCIENCES’ FOUNDER, PRESIDENT AND CEO ON COVID-19

March 25, 2020

At Castle Biosciences, we recognize that this is a challenging time, perhaps more so for those who are diagnosed with cancer. As the COVID-19 pandemic evolves, we remain committed to serving patients who have been diagnosed with melanoma and the clinicians who treat them. We have adjusted our operations in an effort to ensure that we are able to provide uninterrupted access to our proprietary risk of recurrence and metastasis tests. It is also our priority to keep our employees and their families safe and help the communities in which we live and work reduce the number of people impacted by the virus.

Within the first weeks following the diagnosis of cutaneous melanoma, important treatment plan decisions are implemented based upon a patient’s individual risk of recurrence. During these critical first weeks, the results from our proprietary DecisionDx-Melanoma test enable clinicians to make more informed treatment plan decisions. In order to provide uninterrupted access to our DecisionDx-Melanoma test, we have made adjustments to our operations. These adjustments are intended to help keep our employees safe and comply with federal, state and local guidelines, including those regarding social distancing. Importantly, as it relates to the care of cancer patients, these adjustments are expected to help ensure there are no impacts to the access of our DecisionDx-Melanoma test or the turnaround time in reporting test results. For those patients diagnosed with uveal melanoma and their clinicians, we have made similar adjustments to our DecisionDx-UM test workflow, without sacrificing turnaround time. Additionally, based upon the analysis of our supply channel, we believe we have adequate reagent and consumable inventory levels and do not anticipate an impact on our ability to deliver test results for either test due to supply channel concerns.

We will continue monitoring COVID-19 updates closely and make any additional necessary adjustments to our operating plans, in order to do our part to help stop the spread. We remain committed to serving cancer patients and the clinicians who treat them, and we will continue to keep you informed as appropriate during this rapidly evolving situation.

Like other companies, we are operating with imperfect information around COVID-19 and its impact on our business. Nothing in this statement should be viewed as guidance or a prediction about our current or future performance.

Sincerely,

Derek Maetzold
Castle Biosciences
Founder, President and CEO